Mainz Biomed – pharmaceutical daily

January 11, 2024 Off

Mainz Biomed N.V. strengthens partnership with TestDNA to advance colorectal cancer detection in Poland

Mainz Biomed N.V., a company focused on molecular genetics diagnostics for early cancer detection, is confirming its collaboration with TestDNA at the forthcoming 10th Gdańsk Gastroenterology Symposium scheduled for January 12th–13th, 2024. The joint effort aims to progress the detection of colorectal cancer (CRC) in Poland, with a focus on introducing innovative approaches that can improve treatment choices and elevate survival rates through early identification of the disease.

October 4, 2023 Off

Mainz Biomed launches ColoAlert with Bioclinica in Romania

By Dino Mustafić

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, has launched its flagship product, ColoAlert — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) – with its partner Bioclinica, a leader in the Romanian healthcare sector.

August 16, 2023 Off

Mainz Biomed’s colorectal cancer detection test revenue up 108% for half year 2023

By Dino Mustafić

Mainz Biomed has reported half year results, in which the main point was expanding international commercialization for its colorectal cancer detenction test, ColoAlert, which in turn has seen revenues for the first six months of 2023 at $499 049, representing an increase of 108% compared to the first half of 2022.